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Abstract 
MicroRNAs (miRs, miRNAs) are small molecules of 18–22 nucleotides that serve as important regulators of gene 
expression at the post-transcriptional level. One of the mechanisms through which miRNAs regulate gene expression 
involves the interaction of their “seed” sequences primarily with 3′-end and more rarely with 5′-end, of mRNA tran-
scribed from target genes. Numerous studies over the past decade have been devoted to quantitative and qualitative 
assessment of miRNAs expression and have shown remarkable changes in miRNA expression profiles in various dis-
eases. Thus, profiling of miRNA expression can be an important tool for diagnostics and treatment of disease. How-
ever, less attention has been paid towards understanding the underlying reasons for changes in miRNA expression, 
especially in cancer cells. The purpose of this review is to analyze and systematize current data that explains reasons 
for changes in the expression of miRNAs. The review will cover both transcriptional (changes in gene expression and 
promoter hypermethylation) and post-transcriptional (changes in miRNA processing) mechanisms of regulation of 
miRNA expression, as well as effects of endogenous (hormones, cytokines) and exogenous (xenobiotics) compounds 
on the miRNA expression. The review will summarize the complex multilevel regulation of miRNA expression, in rela-
tion to cell type, physiological state of the body and various external factors.
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Background
MicroRNAs (miRs, miRNAs) represent a new class of 
single-stranded RNAs of 18–22 nucleotides, which play a 
key regulatory role in gene expression at the posttranscrip-
tional level. One of the key mechanisms of their action is 
interaction of their “seed” sequences with 3′-end, and more 
rarely with 5′-end, of mRNA transcribed from target genes, 
followed by degradation of target mRNA. The reduction 
in the amount of a specific mRNA is an important result 
of this molecular event. MiRs are important regulatory 
molecules in many biological processes. Numerous stud-
ies over the past decade have been devoted to quantitative 
and qualitative assessment of miRNA expression and have 
shown considerable changes in their expression profiles in 
various diseases [1–4]. The most remarkable changes were 
observed in cancer [5–8]. The results of these studies point 
to the profiling of miRNA expression as an important tool 
for diagnostics and treatment of diseases. However, knowl-
edge of the underlying reasons and mechanisms behind 
changes in miRNA expression is still limited. A clear 
understanding of the molecular mechanisms regulating 
miRNA expression would allow an explanation of the vari-
ations in the expression of protein coding genes. Here we 
suggest a generalized scheme of both transcriptional and 
post-transcriptional regulation of microRNA expression 
(Fig.  1). Transcriptional regulation includes changes in 
the expression of a host gene and hypermethylation of the 
promoter of host or microRNA genes. Post-transcriptional 
mechanisms represent changes in miRNA processing and 
stability. In addition, the effects of endogenous (hormones, 
cytokines) and exogenous (xenobiotics) compounds on 
the expression of miRNAs are considered. This review 
summarizes the complex multilevel regulation of miRNA 
expression in relation to cell type, physiological state of the 
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Defects in the miRNA processing
Biogenesis or processing of miRNAs has been extensively 
studied by many groups in recent years [9, 10]. MiRNAs 
can be transcribed by RNA Polymerase II together with 
the host gene (intragenic miRNAs) or independently of 
the host gene with the use of their own promoter (inter-
genic miRNAs). MiRNA’s primary transcripts or pri-
miRNAs have a unique structure that differs from the 
rest of RNA, which is represented by a hairpin and three 
spiral turns, flanked by the segments of a single stranded 
RNA. This can be recognized by a so-called microproces-
sor complex that contains RNA- binding protein DGCR8 
and RNase III Drosha. This complex cuts pri-miRNAs 
and generates a pre-miRNA of 60 nucleotides, represent-
ing the structure of the truncated hairpin with a two- 
nucleotide ledge and a two- spiral midstream. This allows 
miRNA to interact with Exportin-5 and Ran GTPase in 
order to be further sequestered into the cytoplasm. In the 
cytoplasm this protein-RNA complex is recognized by 
RNase III Dicer that cuts pre-miRNA into a mature form 
of miRNA. Interestingly, it has been shown that Drosha 
generates a smaller variety of miRNAs than Dicer [9] and, 
therefore, the ultimate content of miRNAs is dependent 
upon the activity of these enzymes. The factors regulating 
the expression of microRNAs at the stage of processing 
remain under investigation. For example, Pawlicki and 
Steitz [11] observed that pri-miRNA transcripts retained 
at transcription sites due to the deletion of 3′-end pro-
cessing signals are converted into precursor miRNAs 
(pre-miRNAs) more efficiently than pri-miRNAs that are 
cleaved, polyadenylated, and released.
For some exonic miRNAs, such as miR-155, miR-22 
and miR-146a, both unspliced and spliced transcripts 
may serve as primary miRNA transcripts. They are partly 
localized in the cytoplasm and thus not fully available 
for processing to the mature miRNAs [12]. The splicing 
and transport to the cytoplasm may represent a novel 
mechanism to regulate cellular exonic miRNA levels and 
function.
Changes in miRNA expression profiles could also be 
caused by changes in pre-miRNA export into the cyto-
plasm, impaired activity of Dicer/TRBP complex or post-
translational changes in the Ago family of proteins [13, 
14].
Hata and Kashima [5] have reviewed and analyzed vari-
ous defects in miRNA biogenesis and some examples of 
changes in the activity of microprocessor Drosha. A 
variety of somatic and germ line mutations in the genes 
encoding enzymes involved in miRNA biogenesis, such 
as Drosha, DGCR8, Xpo5, Dicer1 and TRBP, were iden-
tified in malignant tumors [13, 15]. Somatic missense 
mutations affecting the RNase IIIb domain of DICER1 
in nonepithelial ovarian cancers were shown [16]. 
The authors concluded that this is a novel mechanism 
Fig. 1 Levels of regulation of microRNA expression
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through which the perturbation of microRNA processing 
may be oncogenic.
The authors emphasize the importance of studying the 
components of biosynthetic pathways in miRNA biogen-
esis, in order to identify novel regulatory molecules that 
could serve as potential targets for therapeutic interven-
tion. Another important contributor to miRNA levels in 
the cell is the stability of miRNA, which depends on the 
stage of development or cell type involved. Towler and 
colleagues [17] have reviewed several mechanisms con-
trolling the stability of miRNA. One example is the sim-
ple but effective mechanism, whereby a few nucleotides 
(often adenosines) are added to the 3′-end of miRNA, 
thus promoting its stability. Wyman and co-authors [18] 
indentified multiple enzymes, including MTPAP, PAPD4, 
PAPD5, ZCCHC6, ZCCHC11, and TUT1, which par-
ticipate in this 3′ nucleotide non-templated addition to 
miRNAs. The modifications result predominantly in ade-
nylation and uridylation and are seen across tissue types, 
disease states, and developmental stages.
Another mechanism is the presence of sequences such 
as AU/UA within particular miRNAs that destabilize 
their secondary structure. The percentage of AU or UA 
dinucleotide (in either the 5′–3′ or 3′–5′ orientation), but 
not the total percentage of A  +  U, strongly correlated 
with the half-life of select miRNAs abundant in brain 
[19].
A few proteins have been discovered that can bind 
miRNAs and prolong their half-life. It has also been sug-
gested that interaction of miRNA with its target mRNA 
or with ncRNAs can also affect stability of miRNAs. It 
was shown that HuR, a member of the ElaV family of 
RNA-binding proteins, may suppress the inhibitory effect 
of miRNAs [20]. Argonaute proteins play an impor-
tant role in the regulation of microRNA expression and 
function. It was shown that Argonautes elevated mature 
miRNA expression post-transcriptionally, independently 
of RNase activity [21]. In addition, overexpression of 
Argonaute proteins decelerated miRNA degradation and 
increased miRNA half-life [22].
Finally, miRNA stability can be regulated by specific 
ribonucleases. Recently, Segalla and colleagues [23] has 
shown that ribonuclease DIS3 may regulate the levels of 
the tumor suppressor let-7 miRNAs.
Editing of miRNA may also alter miRNA process-
ing following the changes in Ago complex and target 
mRNA binding. Adenosine to inosine (A-to-I) RNA 
editing of miR catalyzed by adenosine deaminase acting 
on RNA (ADAR) proteins may affect the stability, bio-
genesis, and target recognition of microRNA leading to 
changes in gene expression [24]. Yang and co-authors 
[25] has shown that mature miRNA-142 expression levels 
increased substantially in ADAR1 null or ADAR2 null 
mice. The authors discussed a new function of RNA edit-
ing in the control of miRNA biogenesis.
Adenosine deaminases can cause the changes in 
miRNA abundance and sequence during embryogen-
esis, as demonstrated in transgenic mouse embryos [26]. 
Using high-throughput RNA sequencing, Ekdahl and 
co-authors have shown the increased editing in mature 
miRNA from the mouse transcriptome during brain 
maturation [27]. There is no doubt today that microRNA 
editing plays a significant role in the regulation of miRNA 
activity. Kawahara and colleagues [28] estimated that 
approximately 16  % of human pri-miRNAs are subjects 
to A-to-I editing. Other enzymes like DEAD-box RNA 
helicase 6, DDX6 (p54/RCK) can contribute to post-tran-
scriptional down-regulation of miR-143/145 expression 
by prompting the degradation of its host gene product, 
NCR143/145 RNA in cancer cells [29].
All of the mechanisms above have been proposed based 
on studies in animal models or human cell lines; the rel-
evance to the human disease state, therefore, remains a 
subject for future investigations.
Co‑expression of miRNAs with host genes
Changes in intragenic miRNA expression can occur due 
to changes in the expression of host genes where the 
miRNA is encoded. Several studies have suggested links 
between miRNA expression and transcription factors, 
host genes and targets of mRNAs in various malignant 
tumors [7, 30]. However, experimental proof of this cor-
relation is still lacking. Li and co-authors [31] analyzed 
miRNA expression, transcription factors and their gene 
targets in non-small cell lung cancer. Authors utilized 
several databases of TF-miRNA feed forward loops 
(FFLs) and chose FFLs typical of cancer and showed 
miR-17 (associated with transcription factors E2F1 and 
RB1) as an important family in the regulatory network 
of interaction between miRNA and transcription fac-
tors. Another study demonstrated dependence of miRNA 
expression on a host gene [32]. The authors summa-
rized experimental data as well as observations show-
ing changes in miRNA expression in response to various 
stimuli from the immune system. Two particular miRNA 
expressed in B cells were found- miR-155-5p and miR-
155-3p. These miRNAs are located within the Integration 
Cluster gene (BIC) and are induced in response to vari-
ous stimuli from the immune system. This emphasizes 
the importance of this type of study because of the role of 
miE-155-3p in the immune response and development of 
malignant tumors. Another study showed co-expression 
of miR-208a and its host gene myh6 in rats with heart fail-
ure exposed to a 7-day treatment with isoproterenol [33]. 
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Another interesting aspect is co-expression of miRNAs 
with other miRNAs. Recent studies utilizing transcrip-
tome analysis, including that of Chaulk and cowork-
ers [34], showed that miRNAs are mostly clustered and 
expressed as a single pri-miRNA transcript. For exam-
ple, miR-11 and miR-998 have recently been shown to be 
organized in a cluster and have a co-dependent expres-
sion pattern [35].
Indeed, both intra- and intergenic miRNAs can be reg-
ulated by numerous transcription  factors. For instance, 
transcription  factors HNF1β and HNF1α differently 
regulate serum microRNAs in patients with diabetes 
[36]. Using a genome-wide RNA sequencing analysis, 
Mitxelena and colleagues [37] identified E2F7- regulated 
miRNAs and a new regulatory network that involves 
transcriptional and post-transcriptional  mechanisms 
controlled by E2F7 and miRNAs.
Using target miRNA and TF-miRNA interactions from 
different databases, many investigators create regulatory 
networks for various diseases. Differentially expressed 
genes and miRNAs play key roles in this network. So, 
renal cell carcinoma was classed according to the regula-
tory association of adjacent nodes in the three network 
levels for comparing and analyzing the interacting fea-
tures of each differentially expressed gene. Two of these 
genes, PTEN and TP53, showed a particular feature 
of regulating miRNAs and being targeted by the miR-
NAs: PTEN regulates hsa-miR-21, while TP53 regulates 
five miRNAs (hsa-miR-143, hsa-miR-145, hsa-miR-200, 
hsa-miR-215 and hsa-miR-34a) which in turn target two 
genes, HNF4A and MET [38].
Using the same approach for the identification of tran-
scription factors, miRNAs, and target and host genes of 
miRNAs in adenocarcinoma, the regulatory associations 
between these elements were revealed [39]. It was found 
that TP53 directly regulates 9 miRNAs, consisting of hsa-
miR-29b-1, hsa-miR-192, hsa-miR-194, hsa-miR-200a, 
hsa-miR-34a, has-miR-34b, hsa-miR-34c, hsa-miR-145 
and hsa-miR-143. TP53 may also indirectly regulate 
additional 4 genes, CTNNB1, MET, FHIT and KRAS, 
by regulating these 9 miRNAs. The interaction between 
transcription factors and miRNAs, miRNAs and tar-
get genes and miRNAs and their host gene were inves-
tigated in human pancreatic cancer [40]. The authors 
described a self-adaptation association formed between 
TP53 and hsa-miR-125b. Also they demonstrated sig-
nificant changes in expression of further 16 miRNAs in 
pancreatic cancer. Self-adaptation association was also 
described for hsa-miR-196a-1 and its host gene, HOXB7.
Beyond any doubt, such comprehensive regulatory 
networks associated with various types of cancer can be 
used in the future to develop treatments for cancer and 
metastasis.
DNA methylation
Changes in methylation of the regulatory part of genes 
including miRNAs can serve as one of the mechanisms 
to change miRNA expression. It has been shown that 
hypermethylation of the miR-132 promoter reduces its 
expression, which is associated with a poor prognosis for 
colorectal cancer [41]. The methylated status of miR-34b 
and miR-34c genes is also typical of chronic lymphocytic 
leukemia which allows for the classification of these miR-
NAs as tumor suppressors [42]. It was established that 
methylation of the promoter of the miR-210 gene can sup-
press expression of this miRNA which is an important 
step in the process of angiogenesis [43]. Methylation of the 
promoters of miR-124-2, miR-218-1, miR-218-2 and miR-
34b/c was markedly higher in cervical carcinoma cells with 
an HPV16 infection [44]. Similarly, promoter methylation 
of miR-33b is elevated in stomach cancer [45].
Altered methylation of miRNA encoding genes, associ-
ated with deregulated mature miRNA expression, may be 
related to dietary and lifestyle factors and may contribute 
to cancer development. In a case–control study, Cordero 
and colleagues [46] analyzed DNA methylation levels of 
miRNA encoding genes in prediagnostic peripheral white 
blood cells of patients with colorectal cancer or breast 
cancer. The researchers revealed several differentially 
methylated miRNA genes associated with age, sex, smok-
ing  habits and physical activity. They concluded that 
methylation of miRNAs detectable in the blood may rep-
resent a biomarker for the early detection or the risk of 
cancer. DNA methylation of miRNA promoters, such as 
Hsa-mir-200b cluster, may be considered as a biomarker 
of breast cancer subtype with prognostic value [47]. Pro-
moter hypermethylation was shown to be one of the 
major mechanisms for silencing miR-31 in the triple-neg-
ative breast cancer cell lines [48]. Moreover, both miR-31 
and its host gene LOC554202 are down-regulated in the 
TNBC cell lines of basal subtype and over-expressed in 
the luminal counterparts. These findings are very impor-
tant for our understanding of the nature of TNBC. DNA 
methylation and miRNAs regulation play important role 
in the hereditary breast cancer [49].
Given the complex regulation of miRNA expression, 
the relative contributions of methylation of the promot-
ers of miRNA genes versus their host genes, among dif-
ferent mechanisms is hard to evaluate. Thus, further 
studies on the role of methylation in the regulation of 
miRNA expression together with other mechanisms are 
necessary.
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Effects of endogenous factors and hypoxia
Various physiological and pathological stimuli, such as 
steroid hormones or stress, can affect miRNA expression. 
Several reports claimed that estrogens can affect miRNA 
expression [8, 50]. MiRNAs can also play an impor-
tant role in the resistance of breast cancer to hormonal 
therapy. The empirical data of 53 research papers has 
been analyzed [51]. 7 miRNAs were identified (miR-10a, 
miR-26, miR-30c, miR-126a, miR-210, miR-342, miR-
519a), the expressions of which changed after tamoxifen 
treatment of patients with breast cancer. Using an in 
silico approach, the authors have determined candidate 
miRNAs and their target genes that may be involved in 
resistance to tamoxifen. Experiments utilizing micro-
chip technologies and RT-PCR have showed significant 
changes in miRNA expression in various breast cancer 
cell lines incubated with estradiol [52]. These findings 
can be important for understanding the mechanism of 
breast cancer’s resistance to hormonal therapy. Moreo-
ver, the spectrum of miRNA expression appears to be 
markedly different between ER-positive and ER-nega-
tive breast cancers [53]. Estrogen-induced miRNAs are 
important for adrenomodulin balance – the key regulator 
of cardiac activity among women [54]. MiRNA expres-
sion can also be affected by corticosterone. A study of 
the corticosterone-mediated depression in rats showed 
changes in the expression of 26 miRNAs, which can 
regulate closely related genes involved in the develop-
ment, inflammation and depression [55]. Notably, most 
of the discovered miRNAs possess binding sites on the 
glucocorticoid receptor (GR), which suggests a common 
regulatory mechanism with the genes controlled by GR. 
The authors believe that this is a novel mechanism of GR 
action on the expression of miRNAs, which can aid in 
understanding of the development of depression. Inter-
feron (IFN) can induce miRNA expression [56] and this 
serves as an important component of the host immune 
response during the development of malignant tumors or 
viral infections. For example, in many tumors the expres-
sion of miR-21 is elevated, which in most cases has onco-
genic properties. Bioinformatic analysis of the miR-21 
promoter has showed that STAT3 and NFκB pathways 
may be involved in the regulation of its expression. Yang 
and colleagues have also shown that upon treatment 
of various cell lines with IFN, the expression of miR-21 
was increased three- to five fold. The authors concluded 
that STAT3 and the p65 subunit of NFκB can bind to 
the miR-21 promoter and alter its expression. Notably, 
differentiation of embryonic stem cells induced by reti-
noids is dependent on p53-regulated expression of miR-
34a and miR-145, in response to DNA damaging agents 
[57]. While many endogenous compounds can affect 
miRNA expression, the precise mechanism remains to be 
elucidated.
Different types of hypoxia may affect microRNA 
expression. For example, Kiernan et  al. 2016 discussed 
a possible role of dysregulation of microRNA expres-
sion in microglia or other CNS cells during chronic 
intermittent  hypoxia [58]. MicroRNA expression pro-
file also changes in tumor under the hypoxic condition. 
The role of miRNA in tumor microenvironment has 
only recently become a focus of research. Many factors 
such as hypoxia, variety of cell types like cancer-associ-
ated fibroblasts and macrophages may affect microRNA 
expression [59]. For example, in patients with breast can-
cer, tumor hypoxia is associated with reduced DICER 
expression and global miRNA downregulation in the 
microenvironment [60]. This results in the promotion of 
tumor progression. These findings led to a new under-
standing of the mechanisms of tumor progression. MiR-
NAs are now seriously considered as potential targets for 
therapy of metastasis.
Effects of xenobiotics on miRNA expression
More and more evidence emerges demonstrating the role 
of miRNA in chemically induced carcinogenesis. Experi-
mental data has shown that every carcinogen specifically 
affects the expression of a certain miRNA. Therefore 
miRNAs can serve as markers of toxicity of xenobiotics, 
which can be used for early diagnosis in cancer. Mech-
anisms explaining the changes in miRNA expression 
profiles under the influence of xenobiotics are widely 
discussed in current publications. Thus, it has been 
demonstrated that the expression of 5 miRNAs (miR-
29b, miR-31, miR-101a, miR-130a and miR-199a-5p), 
changes upon treatment of embryonic fibroblasts with 
2,3,7,8-tetrachlordibenzo-p-dioxin (“Agent Orange”) or 
under the influence of ionizing radiation [61]. Changes 
in the miRNA expression were observed (including 5 
up-regulated and 5 down-regulated miRNAs) in hemat-
opoietic progenitor cells in C57BL/6 mice exposed to a 
prolonged 4-week treatment with benzene [62], using 
sequencing techniques. These authors emphasize the 
importance of studying miRNA in hematotoxicity caused 
by exposure to benzene. Expression of miRNAs was 
also markedly affected in human hepatocytes cultured 
with benzo(a)pyrene. With the help of two RNA librar-
ies, the entire transcriptome of these cells was sequenced 
and a novel mechanism of action of this carcinogen was 
proposed [63]. Aflatoxin B1, similar to benzo(a)pyrene, 
is a genotoxic carcinogen that can affect the profile of 
miRNA expression. Lu and colleagues [64], using high-
throughput sequencing, have shown an increase in rno-
miR-34a-5p, rno-miR-200b03p,and rno-miR-429, as well 
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as a decrease in miR-130a-3p, in F344 rat livers treated 
with Aflatoxin B1. These results were confirmed by other 
researchers who have also shown changes in miRNA 
expression (especially miR-410 and miR-122) in HepaRG 
human hepatoma cells in response to Aflatoxin B1 and 
benzo(a)pyrene [65]. These data suggest that changes in 
the miRNA spectrum of expression can reflect the early 
events of non-genotoxic mechanisms of action of these 
genotoxic carcinogens. Expression of miRNAs under the 
influence of carcinogenic compounds can also change 
in response to diet. For example, a combination of cod 
liver oil and pectin, which is digested in GI tract with 
the subsequent release of butyrate, causes an upregula-
tion of certain oncogenic miRNAs, whereas a diet com-
prised of corn oil and cellulose does not cause this effect 
[66]. In this study the authors have also observed changes 
in the expression of 26 miRNAs in intestinal stem cells. 
This reveals the importance of diet in the development 
of toxicity from certain carcinogenic compounds. The 
importance of the diet is confirmed by studies of dietary 
polyphenols with anti-oxidant activity found in many 
fruits, vegetables, and plants. The polyphenols can also 
affect the microRNA expression resulting in the up- 
or down-regulation of expression of genes involved in 
many physiological and pathological processes includ-
ing cancer. Polyphenols can modulate the expression of 
more than 100 miRNAs important for various cellular 
processes such as inflammation or apoptosis [67]. The 
authors of the above publications noted the importance 
of further investigations for validation of miRNAs and 
their targets.
In vivo and in  vitro experiments have showed that a 
wide range of environmental carcinogens can affect the 
expression of miRNAs [68]. The reversibility of an effect 
of chemical compounds on miRNA expression depends 
on the dose and duration of the exposure. Izzotti and Pul-
liero [69] have summarized the published studies inves-
tigating various mechanisms of carcinogenesis such as 
DNA damage, interaction of p53 with miRNA, muta-
tions in miRNA genes caused by electrophilic metabo-
lites of carcinogens and defects in DICER activity. Using 
in silico modeling, the authors demonstrated that muta-
gens can impair the process of miRNA formation from 
pre-miRNA. This led to the proposition that inhibition of 
the miRNA synthesis can be an adaptive mechanism in 
response to stress caused by chemical compounds.
Data on the changes in expression profiles of miRNAs 
in response to genotoxic (benzo(a)pyrene, Aflatoxin B1, 
N-nitroso-compounds, urethane) and non-genotoxic 
(arsenic, phenobarbital) carcinogens have been summa-
rized [6]. In an attempt to understand the mechanism 
the authors propose a direct effect of carcinogens (inter-
action with miRNAs with the formation of adducts) and 
an indirect effect, for example, through inactivating the 
enzymatic complex DICER. The authors emphasized 
the importance of research, investigating the action of 
chemical carcinogens on miRNAs, as early markers of 
the carcinogenic process. Our research findings have also 
demonstrated that benzo(a)pyrene and DDT can affect 
the expression of miRNAs in the reproductive organs of 
female rats [70]. The majority of chemical compounds 
that humans and animals are exposed to on a daily basis 
is transformed in the liver and can therefore have a carci-
nogenic effect on this organ. Thus, miRNAs can play an 
important role in the underlying mechanism of chemi-
cally induced hepatocarcinogenesis [71]. Together this 
data suggests that miRNA expression can be affected by 
a diverse range of chemical compounds and that these 
effects depend on the cell type, developmental stage 
and gender. There is emerging evidence that exogenous 
factors can influence epigenetic modifications, such as 
DNA methylation, histone modifications and mitochon-
drial damage [69, 72, 73]. Gained knowledge on effects 
of xenobiotics on miRNA expression can also be used to 
assess toxic effects under chronic and acute conditions 
[74]. Thus, miRNAs are prospective targets in the evalu-
ation of toxic effects of chemicals from the environment 
that often serve as a trigger for the development of vari-
ous diseases, including cancer.
The role of miRNAs in other human pathologies is also 
being actively investigated with the use of animal models. 
It has been shown that doxorubicin causes an increase in 
miR-208a expression and apoptosis of cardiomyocytes 
in female Balb/C mice, suggesting the potential use of 
this miRNA for the prevention of cardiotoxicity caused 
by this anticancer drug [75]. New miRNAs from miR-33 
family have also been identified as important regulators 
of cholesterol metabolism, expression of which changes 
upon treatment of Hep2G cells with statins [76].
Harmful habits like smoking and alcohol consumption 
can affect the expression of microRNAs. Alcohol depend-
ence causes dysregulation of miR expression in human 
brain. It was suggested that miRNAs may have a pivotal 
role in the reorganization of synaptic connections and 
long-term neuroadaptations in alcohol dependence [77]. 
The recent findings suggest that chronic alcohol  con-
sumption may affect the microRNA regulating the synap-
tic mRNA expression [78]. Dysregulation of microRNA 
expression in response to alcohol was also shown in the 
medial prefrontal cortex of rats [79]. Elevated level of 
extracellular vesicles/exosomes and exosome-associated 
miRNA was recently found in both the serum of alcohol-
fed mice and in the plasma of alcoholic hepatitis patients 
[80]. Alcohol induces dysregulation of miR-30a and miR-
934, which may play crucial roles in the pathogenesis and 
progression of head and neck squamous cell carcinoma 
Page 7 of 10Gulyaeva and Kushlinskiy  J Transl Med  (2016) 14:143 
[81]. All these recent data are prompting researchers to 
reconsider the toxic effects of alcohol. Future investiga-
tions of the alcohol-mediated pathways in miR will help 
to improve our understanding of alcohol-associated dis-
eases and advise new treatment options.
Tobacco smoking  remains an important risk factor 
for cancer, especially for lung cancer. It was shown that 
cigarette smoking can change microRNA profile in many 
human organs and induces the change of plasma miRNA 
expression profiles in healthy subjects. Using microarray, 
Shi and co-authors [82] identified 24 up-regulated and 11 
down-regulated plasma miRNAs in young healthy smok-
ers. The authors concluded that the changes in miRNA 
expression profile caused by smoking can be viewed as 
risk factors for cancers (especially leukemia and lym-
phoma), cardiovascular disease, and metabolic syndrome 
in young adult smokers. Earlier it was also shown that 
serum miRNA profiles differed in nonsmokers, smok-
ers, and lung-cancer patients [83]. The authors of this 
report found that let-7i-3p and miR-154-5p were signifi-
cantly down-regulated in the sera of smokers and lung-
cancer patients, and these changes can be considered 
as potential biomarkers of smoking-related lung cancer. 
Xi and colleagues [84] demonstrated epigenetic mecha-
nisms that regulate miRNA expression during human 
pulmonary carcinogenesis and suggested utilization of 
chromatin remodeling agents for lung cancer therapy 
to restore the expression of miR-487b. The latter is up-
regulated upon exposure to cigarette smoking conden-
sate. In the last decade, a number of published articles 
demonstrated a strong correlation between various miR-
NAs, their targets and smoking-regulated genes in can-
cer. However, the clear understanding of the mechanisms 
of miR regulation by cigarette smoking is lacking so far. 
One of the suggested mechanisms might be the activa-
tion of Aryl hydrocarbon receptor (AhR) by tobacco 
smoke resulting in the changes of its target genes includ-
ing ‘host’ miR genes. This is supported by the recent data 
of Nguyen and co-authors [85] which showed that AhR 
mediates the immune regulatory mechanism of rheuma-
toid arthritis. The authors argue that tobacco smoke is a 
well-known environmental risk factor for development of 
rheumatoid arthritis since it contains AhR agonists, such 
as 2,3,7,8-tetrachlorodibenzo-p-dioxin, 3-methyl cholan-
threne, and benzo[a]pyrene.
Mechanisms of action of xenobiotics on miR expres-
sion can be mediated by nuclear receptors. For example, 
some miRs are expressed through AhR-dependent mech-
anism [86, 87]. It has been shown that phenobarbital-
mediated activation of constitutive androstane receptors 
(CAR) is accompanied by the decrease in miR-122 in liver 
[88]. Time and dose-dependent effects of phenobarbital 
on the miR expression in rat liver were demonstrated 
recently [89]. It was also shown that expression of micro-
RNA can be regulated by farnesoid X receptor (FXR) 
which is important for lipid metabolism [90]. However, 
future experiments will be needed to elucidate the func-
tional relationship between nuclear receptors and miR 
expression.
Conclusion
The expression of microRNAs can be regulated on multi-
ple levels (Fig. 1). At the transcriptional level, expression 
of microRNA genes can change together with (intragenic 
miRNAs), or independently of (intergenic miRNAs), their 
host genes. Intergenic miRNAs have their own promot-
ers, are expressed independently and can be regulated by 
separate transcription factors. In both cases, the expres-
sion of microRNA can change due to different mutations 
or can be regulated by methylation of the promoter. On 
the post-transcriptional level the expression of microR-
NAs can be downregulated due to changes in the activ-
ity of key miRNA biogenesis enzymes, such as Dicer and 
Drosha. Activity of these enzymes can also be affected 
by mutations or epigenetic modifications. Moreover, 
chemical compounds of endogenous origin (hormones, 
cytokines), and exogenous origin (xenobiotics), can alter 
microRNA expression. Activation of nuclear receptors 
by xenobiotics as their ligands can induce expression of 
both intergenic and intragenic microRNAs. All the data 
regarding changes in miRNA expression analyzed in this 
article provides insights into comprehensive mechanisms 
of regulation of microRNA expression, dependent on 
cell type, physiological conditions and external factors. 
It is clear that microRNAs offer potential targets for the 
diagnosis, prognosis and treatment of a wide variety of 
diseases. However in order to achieve this goal, further 
theoretical and experimental studies of the mechanisms 
of miRNA expression are crucial.
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